Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

Abbott reported third-quarter 2026 sales of $13.013 billion, up 14.5% year over year as reported and 7.0% on a comparable basis; adjusted diluted EPS rose 9.2% to $1.42, while GAAP diluted EPS fell 43.6% to $0.53. The company reaffirmed its full-year adjusted EPS guidance midpoint and narrowed the range to $5.50–$5.55, with comparable sales growth projected at approximately 6.0%. GAAP operating earnings declined 34.0%, with results including $1.557 billion of specified after-tax charges, including legal settlements. Abbott also highlighted multiple product approvals and launches and declared a quarterly dividend of $0.63 per share.

Analysis

Underlying momentum is better than the GAAP headline but less broad than reported growth suggests: acquisition-adjusted comparable growth accelerated, while the large GAAP/adjusted EPS gap and sharply higher interest and amortization costs make the acquisition’s earnings and cash conversion the key underwriting questions. The $1.42 adjusted EPS and reaffirmed guidance reduce near-term estimate risk; they do not establish that integration costs, litigation exposure, or financing burden are behind Abbott. Verify management’s bridge from adjusted earnings to free cash flow and net debt on the call.

The quality split matters: cancer diagnostics and medical devices are growing, but nine-month Nutrition remains down and Rapid/Molecular Diagnostics is contracting. A single strong quarter is not enough to assume a broad-based recovery. Longer term, Abbott’s blood-based CRC screening could expand access, but it also creates potential portfolio tension with Exact Sciences’ Cologuard; the net value depends on channel positioning, reimbursement, and whether SimpleScreen grows the category or shifts existing demand. Guardant Health is an external competitor to watch. Exact Sciences is described as acquired, so do not treat EXAS as a standalone exposure without confirming its current listing and security status.

Near term, the conference call is the catalyst for acquisition financing, integration, legal-settlement cash timing, and 4Q execution. Over 1–3 months, track guidance delivery and comparable growth by segment; over 6–18 months, product adoption and integration economics matter more than launch announcements. Contrarian point: neither the 14.5% reported sales increase nor the GAAP EPS decline alone captures the investment case. The risk is that adjusted metrics understate a persistently higher cost base, not simply one-off noise.

Key Decisions for Investors

• ABT: Do not chase the reported-sales headline. Keep exposure neutral pending the call; consider adding only on post-earnings weakness if management substantiates free-cash-flow conversion, acquisition-related leverage, and the unchanged full-year EPS midpoint.
• On the call, require a quantified bridge for acquisition-related interest, amortization and integration costs, plus cash payments for litigation and regulatory matters. A rising net-debt burden, weaker cash conversion, or guidance reduction would falsify the constructive read and argue for reducing ABT exposure.
• Track quarterly comparable growth in Nutrition and Rapid/Molecular Diagnostics alongside medical-device growth. Continued contraction in either weak segment would undermine the diversification narrative; sustained improvement would make the current growth mix more durable.
• Treat SimpleScreen as a watch item, not a near-term earnings catalyst: verify launch uptake, reimbursement, and whether Abbott positions it alongside or against Cologuard. Monitor Guardant Health for competitive or market-share evidence; do not initiate an EXAS position without confirming whether the security remains independently tradable after the acquisition.